Dear Christopher,

Professor Jean Bourhis(key collaborator with Pignon/MACH-NC meta analysis,Lancet 2000)came over from Paris yesterday to speak to a UK head and neck conference. The meta analysis has been considerably expanded and collated by Bourhis/Pignon, though not yet submitted for publication. He confirms the previously submitted view that there is no firm evidence to justify using RT with Carboplat as a single agent alternative to standard Cisplat in patients considered unsuitable for Cisplat eg with past history of vasculopathy. Indeed he suggested there was more evidence to support the use of Cetuximab in this patient group than Carboplatin. I have obviously given detailed comments in the written appeal process. In relation to highlighting the distinction between KPS and comorbidity there was a useful discussion at the Verbal Appeal hearing in August which together with my previous written comments I think suffices.

| Dr Nick Slevin on behalf of Royal College Radiologists | |
|---|--|
| Delivered via MessageLabs | |
| The email address replaced with | is being phased out and has been please amend your records accordingly. |
| *************************** | ************************************** |
| intended recipient. If you have rece | d with it are confidential and solely for the use of the eived this e-mail in error you should not disseminate, he sender immediately and delete this e-mail from your |
| ********* | ************ |